Intech Investment Management LLC Makes New Investment in HilleVax, Inc. (NASDAQ:HLVX)

Intech Investment Management LLC acquired a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 12,647 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Braidwell LP bought a new stake in HilleVax during the third quarter valued at about $1,873,000. Verition Fund Management LLC bought a new position in shares of HilleVax during the 3rd quarter valued at approximately $331,000. Zacks Investment Management increased its holdings in HilleVax by 411.9% in the 3rd quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock worth $163,000 after acquiring an additional 74,673 shares in the last quarter. Jane Street Group LLC raised its stake in HilleVax by 81.7% during the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after acquiring an additional 35,546 shares during the period. Finally, Barclays PLC lifted its holdings in HilleVax by 255.6% during the third quarter. Barclays PLC now owns 42,033 shares of the company’s stock valued at $74,000 after purchasing an additional 30,213 shares in the last quarter. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Price Performance

Shares of NASDAQ HLVX opened at $1.59 on Friday. The stock has a market cap of $79.19 million, a PE ratio of -0.51 and a beta of 0.76. HilleVax, Inc. has a 1 year low of $1.55 and a 1 year high of $16.66. The firm has a fifty day moving average price of $1.82 and a 200-day moving average price of $1.86.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.